

LACunar Intervention (LACI) Trial-3: Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke



Trial Information

Co-Sponsors	The University of Edinburgh & Lothian Health Board (ACCORD)
Funder	National Institute for Health and Care Research NIHR Health Technology Assessment (NIHR HTA)
Sponsor Reference	AC24127
IRAS number	1008629
ISRCTN number	44436843
REC number	24/SS/0095
Chief Investigator	Professor Joanna M Wardlaw

Contact information

Trial Coordinating Centre	Centre for Clinical Brain Sciences (CCBS) University of Edinburgh Chancellor's Building 49 Little France Crescent Edinburgh, EH16 4SB
Trial Manager	Kasia Adamczuk
Email	laci-3@ed.ac.uk
Telephone number	0131 465 9592
Website	https://www.laci-3.ed.ac.uk

Contents

1. Introduction.....	3
2. User account access	3
3. Main menu and Visit details	3
4. Randomising a new participant	4
5. Submitting the randomisation form.....	6
6. Contact database	7
7. Baseline and Follow-up CRFs	7
8. Entry of missing data.....	9
9. Data queries and corrections.....	9
10. Prescription issue form	12
11. No set visit form	13
12. SAE and Outcome reporting	13
13. Data correction requests	14
14. Technical support.....	14
15. Revision History.....	15

1. Introduction


This document provides guidance to assist users in completing the electronic case report forms (eCRFs) on the LACI-3 trial website. Users can access the database at the following address:

https://stroke.nottingham.ac.uk/sif/live/sif_login.php?sid=LACI-3

2. User account access

New users must be on the signed delegation log, a copy of which must be sent to the trial office along with a current email address.

The trial office will register users who will then receive login details via email. Users will be required to change their password at the first login. Users should never share their username and password with anyone.



LACI-3 investigator ID:

Password:

Login

3. Main menu and Visit details

Once logged, proceed to the 'participant list' page where you will see a participant ID list with visit details. Trial documents including PDFs of all CRFs can be accessed via the link to 'trial documents for downloading' at the top right.



Printable forms Trial documents for downloading Data reports

Total number of trial participants recruited: 0 All UK hospitals

Participant ID/age at randomisation	Event date	Randomised (day 0)	Contacts/ documents	Baseline	Week 1-2 follow-up	Week 3-4 follow-up	Prescription issue	No set visit	Outcomes	SAEs
Once recruited, trial participants will be listed here.										

4. Randomising a new participant

To randomise a new participant, click the link at the top left:

[Randomise a new participant](#)
[Printable forms](#)
[Trial documents for downloading](#)
[Data reports](#)

Total number of trial participants recruited at this centre: 0

Local time: 26 Jun 2025 13:40 BST

C001: Edinburgh, Royal Infirmary of Edinburgh

Participant ID/age at randomisation	Event date	Randomised (day 0)	Contacts/ documents	Baseline	Week 1-2 follow-up	Week 3-4 follow-up	Prescription issue	No set visit	Outcomes	SAEs
Once recruited, your trial participants will be listed here.										

This will open a data entry form with a reminder of the inclusion and exclusion criteria.

Section A: Inclusion/exclusion criteria and consent

Inclusion criteria

- Aged 30 years old and above
- Clinical stroke syndrome compatible with a lacunar stroke and brain imaging (MRI preferred but CT allowed) at the time of the stroke shows a relevant recent small subcortical infarct, or if no relevant infarct then no other explanation for symptoms is seen
- Genetic forms of SVD (e.g. CADASIL) may be included if they present with a lacunar stroke
- Capacity to give consent in the opinion of the PI or any delegated member of the research team

Exclusion criteria

- Less than 24 hours since onset of the lacunar stroke
- Patient on dual antiplatelet drugs (see additional exclusion, below)
- Stroke mechanism with definite treatment indication (e.g. cardioembolism, ipsilateral carotid stenosis)
- Other explanation for the lacunar stroke symptoms (i.e. recent cortical infarct, haemorrhage or tumour)
- Other active neurological disease (e.g. brain tumour, multiple sclerosis, recurrent seizures, neurodevelopmental disorder - well-controlled epilepsy present prior to the lacunar stroke, a single seizure at onset of the stroke, or provoked seizure, is not an exclusion)
- Contraindication to both trial drugs in section 4.3 of the SPCs (patients with a contraindication to one trial drug may still be randomised to the other trial drug)
- Indication for either trial drug (patient already prescribed one trial drug may still be randomised to the other trial drug)
- Dependent - mRS cannot be 3-5
- Clinical diagnosis of dementia
- Planned surgery during the trial period including carotid endarterectomy.
Note prior and apparently successful carotid endarterectomy (or other surgery) is not an exclusion criterion and patients who would otherwise be eligible but require endarterectomy first may be randomised after recovery from successful endarterectomy
- Unable to swallow
- Diagnosis of hypotension, defined as sitting systolic blood pressure less than 100 mmHg
- History of drug overdose or attempted suicide
- Unlikely to be available for follow-up at 18 months
- Unlikely to comply with study procedures and follow-up procedures for whatever reason (e.g. history of poor medication compliance) in the opinion of the randomising physician

1 Data entry

2 Enter missing data

3 Correct errors (shown in red)

4 Check and submit

Exclusion criteria for both drugs are listed. Review these and complete the check box for both drugs.

Cilostazol exclusion criteria	
• Allergy to Cilostazol • Already prescribed Cilostazol • Any contraindication to Cilostazol • Patient is on a prohibited medication: ◦ Warfarin ◦ Acenocoumarol (Sinthrome®) ◦ Phenindione ◦ Dabigatran (Pradaxa®) ◦ Apixaban (Eliquis®) ◦ Rivaroxaban (Xarelto®) ◦ Edoxaban ◦ Heparin ◦ Dalteparin (Fragmin®) ◦ Enoxaparin (Clexane®) ◦ Tinzaparin (Innohep®) ◦ Omeprazole – can be switched to Lansoprazole or other Proton Pump Inhibitor ◦ Anagrelide ◦ Clarithromycin ◦ Erythromycin ◦ Diltiazem (Tildiem®) ◦ Itraconazole (Sporanox®) ◦ Boceprevir (Victrelis®) ◦ Ritonavir (Norvir®) ◦ Telaprevir (Incivo®) ◦ Ketoconazole (Nizoral®) • Active cardiac disease (atrial fibrillation, myocardial infarction in past 6 months, active angina, symptomatic cardiac failure) • Bleeding tendency (platelets under $100 \times 10^9/L$, active peptic ulcer, taking anticoagulant medication)	
A3	Have the Cilostazol eligibility criteria been fulfilled? ☐ Yes ☐ No

If criteria are not met, the CRF cannot be completed.


Participant details, SVD score, blood pressure, medications, mRS, NIHSS and MoCA are collected.

Some questions offer a not applicable option on the right hand column. Ensure this is completed where appropriate.

B6	Date/time of onset of index stroke (dd-mmm-yyyy hh:mm 24hr)	- Day - - Month - - Year -	:		
B7a	Date/time of first CT head scan after index stroke (dd-mmm-yyyy hh:mm 24hr)	- Day - - Month - - Year -	:		[Select...] v
B7b	Date/time of first MRI head scan after index stroke (dd-mmm-yyyy hh:mm 24hr)	- Day - - Month - - Year -	:		[Select...] v

Some questions have a pop up guide with more information to assist completion.

B8a	Acute stroke lesion present to explain symptoms, on either CT or MRI brain scan	☐ Yes ☐ No
-----	---	--



5. Submitting the randomisation form

When you submit, you will be prompted to check all answers are correct prior to submitting

Form submission sign off	
Are any values missing due to tests not done (or measures not taken), or because data are unknown and every effort has been made to find the data – i.e. 'Not done' / 'Not known'?	☐ Yes ☒ No
Comments If any values are missing, please provide a full explanation explaining why and submit for further options	
If applicable to your site, please remember to record the drug prescription on the participant's drug chart	Submit

You will then be given the randomisation result and prompted to enter the participant contact details [image from the demo database, this is not a real participant]:

Thank you for your submission – your randomisation record has been successfully submitted to the database.

This participant was randomised to the **None** treatment group.

None (neither Cilostazol nor ISMN)

Please **do not** write down the treatment group.
You may wish to print this page.

Print

- To view the data you have entered, please [click here](#).
- Please enter the participant's contact details into the [secure vault](#).** These will be encrypted and stored separately, **not** in the pseudonymised database that you are currently logged into for LACI-3.



Switch to the secure vault site


Please don't forget to provide us with copies of the following.

- Consent form(s)

LACI-3 participant details	
Participant ID:	C001-0004
Initials:	B-G

Please print the randomisation result for your records. This needs to be filed in the ISF and provided to pharmacy if applicable. The randomisation allocation does not appear on the automatically generated notification email due to blinding in place for the LACI-3 central team.

Should you need to view the randomisation result again, you can go to the participant list and click on the linked trial number. This is only available for the first 2 weeks after randomisation.



All CRF questions must be completed prior to submission

Drafts can be saved and the form completed at a later date

Forms are accessed by entering the participant DOB and initials

6. Contact database

Following completion of the randomisation form you will need to complete the contact details in the secure database. Please double check all details are valid and up to date.

- Please make sure to include the participant's telephone number, which is required for follow-ups.

Form submitted by: **DEMO investigator**
(DEMO Edinburgh Centre, Edinburgh)

LACI-3 participant ID: **C001-0004** (male, 100 years old)

Surname: (This was previously submitted) [Change](#)

Forename(s): (This was previously submitted) [Change](#)

Middle initials:

Permanent address:

Post code:

Follow-up telephone number:

Alternate address:

Alternate telephone number:

Email address:

Date of birth: / / (dd/mm/yyyy)

NHS/CHI/H+C number: Please answer

Hospital number:
(not centre ID)

Name of hospital ward(s):

7. Baseline and Follow-up CRFs

Once randomisation is complete, you will be able to access the baseline CRF

Participant ID/age at randomisation	Event date	Randomised (day 0)	Contacts/ documents	Baseline	Week 1-2 follow-up	Week 3-4 follow-up	Prescription issue	No set visit	SAEs	Centre transfers
C001-0001	81	3 Mar 2025	10 Apr 2025	Y Y	10 Apr 2025	10 Apr 2025	10 Apr 2025	Select ×1	Select ×1	Select ×1
C001-0002	79	1 Jan 2024	11 Apr 2025	Y N	11 Apr 2025	22 Apr 2025	6 May 2025	Select	Select	Select
C001-0003	76	7 Jan 2023	18 Apr 2025	Enter	18 Apr 2025	29 Apr 2025	13 May 2025	Select	Select	Select ×1
C001-0004	100	3 Feb 2023	2 May 2025	Y N	2 May 2025	13 May 2025	27 May 2025	Select	Select	Select

[Switch to mobile site](#)

Information is collected on medical history, risk factors, index stroke, carotid status, investigations, employment and some assessments (MMSE, Trails, ED-5D-5L).

Section A: Participant details		
A1	Date of data collection (dd-mmm-yyyy)	10 Apr 2025
Section B: Risk factors and past medical history		
B1a	History of treated hypertension?	Yes, prior to index stroke ▾ -
B1b	If hypertensive, what are they on?	Both ▾ -
B2a	History of treated hyperlipidaemia?	Yes, since index stroke ▾ -
B2b	If hyperlipidaemic, what are they on?	Medications ▾ -
B3a	History of diabetes?	Yes ▾ -
B3b	If diabetic, what are they taking?	☐ Lifestyle measures ☒ Oral agents ☒ Insulin ☐ None
B4	History of, or current, atrial fibrillation?	Past ▾ -
B5	History of heart failure?	☒ Yes -
B6	History of ischaemic heart disease?	☒ No -
B7a	History of stroke	No ▾ -
B7b	If yes, which side of brain was affected? <i>If midline, indicate main side affected</i>	- Not applicable ▾

The ideal date of the follow up appointments will appear in the participant table once the baseline is completed. Aim to complete the visit as close to this date as possible

The 1-2 and 3-4 week follow up CRFs includes details of participant status at follow up

Section A: Participant details		
A1	Date of data collection (dd-mmm-yyyy)	10 Apr 2025
A2	Status of the participant	☒ Available - postal questionnaires returned
A3	If died, date of death (dd-mmm-yyyy)	- Not applicable ▾
A4	Explanation if follow-up cannot be completed. <i>If deceased, please supply as much information as possible (cause, where, etc.)</i>	- Not applicable ▾

If died since last visit, please complete an outcome CRF.

Section B: Symptoms		
B1a	Headache	☒ No -
B1b	If present did it stop normal activities?	- Not applicable ▾
B1c	Frequency	- Not applicable ▾
B2a	Palpitations	☒ No -

Symptoms, medication, BP and outcomes are also collected.

8. Entry of missing data

Some questions may provide "Not applicable", "Not done" and/or "Not known" options.

- Not applicable - should be used if a measure was not required for that participant
- Not done - should be used if data are unavailable, either because a measure was not taken or a test was not performed
- Not known - should be used if the data are unknown, and every effort has been made to find the data

For each question on a CRF, you should either enter a value in the central column(s) or use the drop-down lists in the right-hand column to indicate why the value is missing - but not both. A response must be given in this way for every numbered question on the CRF.

The "Not done" and "Not known" options relate to missing data. Some of these options may be hidden when a LACI-3 online CRF is first accessed, i.e. before any data have been submitted. This is because the options provided reflect the data we need to collect for proper analysis of the trial.

However, some required data may still be missing for legitimate reasons. For example, it may not be possible to measure a participant's weight in the emergency department. In such cases, to access the hidden "Not done" and "Not known" options, please go to the bottom of the page and set the missing data control to "Yes". Enter a full explanation and submit the form.

After this, you can complete the CRF as usual and submit. Check through your answers and re-submit to store the data that you have entered.

Note that once the hidden options have been revealed, they will continue to be displayed even if you have no missing data (i.e. when none of the questions have "Not done" / "Not known" selected). If no data are missing, please set the control at the bottom of the page to "No" and re-submit. In this case no explanation is required so may be left blank, however relevant comments may always be entered

9. Data queries and corrections

The coordinating centre may raise data queries if there is missing data or if something is not quite right. You will see an alert for any outstanding data queries when you click on participant list, click on this and it will show open queries for actioning

There is one active data query

Please click on the CRF where the data query is located i.e. in this example Day 7. You can also they can also click on the issue ID (glint+seesaw) to go directly to the specific query/questions.

Open queries for C001 NOTTINGHAM, Nottingham DEMO Hospital, UK

Participant ID	CRF	Question IDs/query details	Date/time/ data query ID	Assigned to
C001-0002-ONK	Day 7	☐ A2c 'Test' isn't a valid reason.	6 Oct 2022 12:50 glint+seesaw	Haywood, Lee centre 1

Found one matching data query

The data query will show above the question where the data is to entered/amended. Please click on the link for 'data correction request'

A2b	Date/time of first dose (dd-mmm-yyyy hh:mm 24hr)	(No data) (No data)	
Query raised on 6 Oct 2022 Data query ID: glint+seesaw		See A2c 'Test' isn't a valid reason. Assigned to: Haywood, Lee centre 1 (ljhaywood_c1)	
• Please submit a data correction request (see the button at the top of this page) • You may need to update the CRF comments, or contact us about this data query			
A2c	Explanation if treatment not received or data missing	Test	

You will then complete a participant identity check.

Data correction request – participant identity check

It is essential that the data collected are entered against the correct trial participant.

Please complete the following identity questions to continue to the data correction request CRF.

Trial number 2

Initials

Sex ☐ Male ☐ Female

Date of birth - Day - - Month - - Year -



The data correction request form **does not** support draft records.
The form **must** be submitted completely, otherwise the data will be lost.

You will need to complete a table detailing the change made and the reason:

A5: Question ID and label is the number and title of question and the data originally entered


A6: Enter question ID of where the new data is to be entered, and the values that should appear once the CRF record has been amended

A7: Please enter the reason for the change

A5	Existing data Please list each: <i>Question ID</i> <i>Question label</i> <i>Data shown on report</i>	A2c: Explanation if treatment not received or data missing - "Test". Explanation for missing data: "Transferred before day 7".
A6	New data Please list each: <i>Question ID</i> <i>New value(s)</i>	A2c: "Participant transferred for surgery before full dose given." Explanation for missing data: "Transferred on first day for surgery".
A7	Reason for change	Required full explanation had not been given.

You can submit a data correction request without a data query being raised by the coordinating centre e.g. if you put a comment that the EQ-5D-5L was not done at the time and would update the data later. When the data is available click on the 'submit a data correction request' button at the top of the eCRF.

As before, you will need to complete the participant identity check to access the data correction request form. If applicable, please also give existing/new text for the full explanation for missing data (state 'n/a' for 'New data' if text to be removed).



[list](#)

Section A: Inclusion/exclusion criteria and consent

Inclusion criteria

- Adults within 4.5 hours of onset of acute spontaneous ICH (confirmed on brain imaging)
- When onset of symptoms is unknown, patient must be within 4.5 hours of symptom discovery and have no other exclusion criteria

Exclusion criteria

- Patient with a known indication for TXA treatment (e.g. traumatic brain injury)

[Submit a data correction request](#)

Common issues:

- Update data for all affected questions in a single request, when possible - especially related questions
- Use one line per question
- Make sure that existing data are always given, stating "Not done" and "Not known" where previously missing
- Do not list questions whose values have not changed

Prescription details need to be entered into the CRF using the Prescription issue form link next to the participant visit details.

Add new prescription issue record

Record ID	Date issued	Duration of prescription	Tablets dispensed/ count
No prescription issue records have been submitted for this participant yet.			

Section B: Tablets dispensed		
	Count	Brand name
B1	Number of Cilostazol 50mg tablets dispensed	
B2	Number of Cilostazol 100mg tablets dispensed	
B3	Number of ISMN 20mg tablets dispensed	
B4	Number of ISMN 40mg tablets dispensed	
B5	Number of ISMN XL 25mg tablets dispensed	
B6	Number of ISMN XL 30mg tablets dispensed	
B7	Number of ISMN XL 50mg tablets dispensed	
B8	Number of ISMN XL 60mg tablets dispensed	

Record ID	Date issued	Duration of prescription	Tablets dispensed/ count		
#1	Thu 10 Apr 2025 	3 months	Cilostazol	50mg	x1
			Cilostazol	100mg	x1
			ISMN	20mg	x1
			ISMN	40mg	x1
			ISMN XL	25mg	x1
			ISMN XL	30mg	x1
			ISMN XL	50mg	x1
			ISMN XL	60mg	x1

11. No set visit form

If an unscheduled assessment is performed, then it should be captured in the database using the no set visit form. These include details about stopping or changing medications, safety and outcome events and withdrawals.

Section A: No set visit details	
A1 Date of data collection (dd-mmm-yyyy)	02 May 2025
A2 Type of no set visit	☐ Medication stopped ☐ Medication changed ☐ Query about medication ☐ Outcome event ☐ Potential AE/patient side effects (report SAEs to sponsor) ☐ Potential deviation (report to sponsor) ☐ Participant withdrawn ☐ Death ☐ Other (please specify)
A3 Details of visit/contact	
A4 Has there been a change in the status of the participant?	☐ No change ☐ Permanently stopped treatment (continue follow-ups) ☐ Withdrawn from study IMP, continues in follow-up ☐ Withdraw from study IMP and follow-up, continue collection of clinical and safety data from medical notes ☐ Withdrawn consent to be contacted about other research

12. SAE and Outcome reporting

Please refer to the protocol and safety adjudication SOP for details of SAE reporting.

Should an SAE or outcome need to be reported, please complete the form listed next to the participant visits.

The type of event is selected from a drop-down list.


Please select the type of outcome event or Serious Adverse Event (SAE) to add a new record.

[Select...]
[Select...]

Outcome events
Recurrent ischaemic stroke
Transient Ischaemic Attack (TIA)
Brain haemorrhage
Stroke of unknown type
Dementia clinical diagnosis
Myocardial infarction
Major systemic (non-cranial) haemorrhage
Death of cause other than outcomes above

SAEs
Serious Adverse Event


For SAEs, print a pdf of the completed form and email to safety@accord.scot within 24 hours of becoming aware.



The screenshot shows a web browser window displaying the LACI-3 SAE form. The form is titled 'Serious Adverse Event form v0.4' and includes fields for 'Investigator: DEMO investigator' and 'Participant ID: 0001-0010'. A 'Submit a data correction request' button is visible at the top right. The form content includes a table for 'SAE NUMBER 4' with fields for 'Date and time began', 'Date and time reported to investigator', 'When did this event happen with regard to the treatment period?', 'Description of the event, in medical terms', 'Event diagnosis', 'If 'other', please state the medical condition (diagnosis, not treatment)', 'Nature of event', and 'Severity of event'. A 'Submit a data correction request' button is also circled in blue on the right side of the form.

13. Data correction requests

Data must be consistent with the patient's source documentation. Where errors occur or details need to be updated, a data correction request must be completed by following the link at the top of the page of the relevant CRF. These are then actioned by the LACI-3 programmer.



The screenshot shows a web browser window displaying the LACI-3 Randomisation form. The form is titled 'Randomisation form v0.6' and includes fields for 'Investigator: DEMO investigator' and 'Participant ID: 0001-0001'. A 'Submit a data correction request' button is visible at the top right. The form content includes a table for 'Section A: Inclusion/exclusion criteria and consent' with fields for 'Inclusion criteria' and 'Exclusion criteria'. A 'Submit a data correction request' button is also circled in blue on the right side of the form.

14. Technical support

First point of contact for any queries relating to the eCRF is the trial office laci-3@ed.ac.uk
Should a response not be received in a timely manner please contact Lee.Haywood@nottingham.ac.uk

15. Revision History

Date	Version number	Changes applied
25 th June 2025	1.0	N/A
17 th September 2025	2.0	Re-accessing randomisation result added, guidance for missing data and data queries and corrections added